Cutaneous reactions related to systemic immunomodulators and targeted therapeutics

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Targeted therapeutics have revolutionized cancer treatment.
• These novel agents are associated with distinct and frequent dermatologic toxicities.
• Understanding these side effects is essential for patient management.

Purpose of the Study:

• To review the dermatologic events associated with targeted cancer therapies.
• To discuss the challenges in managing these toxicities.
• To explore the correlation between dermatologic toxicity and therapeutic efficacy.

Main Methods:

• Literature review of dermatologic events from targeted agents.
• Analysis of specific drug classes including epidermal growth factor receptor inhibitors, multikinase inhibitors, proteasome inhibitors, BCR-ABL tyrosine kinase inhibitors, and immunomodulatory drugs.
• Discussion of management strategies and correlation with clinical outcomes.

Main Results:

• Dermatologic toxicities from targeted agents are common and varied.
• Different targeted therapies present unique skin manifestations.
• Dermatologic adverse events, particularly rash, may correlate with antitumor activity, response, and survival.

Conclusions:

• Effective management strategies for targeted therapy-induced dermatologic events are necessary.
• The correlation between rash and efficacy highlights the importance of monitoring and supportive care.
• This review provides insights into managing skin toxicities for improved patient outcomes in oncology.